ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

PROK Interest Expense

Cost of servicing the company's debt during the period.

ProKidney Corp.NASDAQ: PROK

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $15K, compared with $0 a year earlier. Trailing-twelve-month interest expense was $19K. Over 3 fiscal years it compounded at -73.5% a year.

Context

  • Interest expense amounted to 0.4% of revenue in FY2025, down 11.4 pp from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $15K or moves back toward the trailing-twelve-month quarterly average of $4.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15K+1400.0% QoQ
Last fiscal yearDec 2025
$4K-55.6% YoY
LTMMar 2026
$19K+171.4% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-55.6%——
3-year CAGR-73.5%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
4K USD
Year-over-year change
-55.6%

Interest Expense vs competitors

How PROK compares with its peers on the latest reported figures

  • PROK's LTM Mar 2026 interest expense of $19K is the 6th highest of the 7 companies compared; the peer median is $950.76K.
  • Its year-over-year change of +171.4% is the highest of 4, against a peer median of -16.7%.
  • Interest expense amounts to 2.1% of revenue for PROK, versus a peer median of 4.3%.
PROK Competitors Peer median
Interest Expense for PROK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$29.05M +30.3%+77.6%6.8%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$4.59M -59.3%-0.8%0.7%
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024$1.04M —+49.2%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$866K ——4.3%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$55K -16.7%+127.9%—
PROKProKidney Corp.LTM Mar 2026$19K +171.4%-73.5%2.1%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding PROK) $950.76K-16.7%+63.4%4.3%

Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00076K893K
Cost of Revenue00000
Gross Profit00076K893K
Gross Margin———100.0%100.0%
Research & Development46.26M82.07M106.71M127.67M114.12M
Selling, General & Admin8.86M70.94M44.82M56.08M51.78M
Operating Expenses55.11M153.01M151.52M183.75M165.9M
Depreciation & Amortization1.98M3.04M3.85M5.43M6.58M
EBITDA(53.12M)(143.99M)(125.59M)(158.49M)(144.62M)
EBITDA Margin———-208542.1%-16194.7%
Operating Income(55.11M)(153.01M)(151.52M)(183.68M)(165.01M)
Operating Margin———-241678.9%-18477.8%
Interest Income2K5.98M22.08M19.75M13.81M
Interest Expense0215K12K9K4K
Other Income / Expenses2K5.77M22.07M19.74M13.81M
Income Before Tax(55.11M)(147.24M)(129.45M)(163.93M)(151.2M)
Pre-Tax Margin———-215701.3%-16931.5%
Income Tax Expense38K896K6M(598K)414K
Net Income(55.15M)(108.03M)(35.47M)(61.19M)(68.99M)
Net Margin———-80507.9%-7725.2%
EPS (Basic)(1.73)(1.76)(0.57)(0.62)(0.52)
EPS (Diluted)(1.73)(1.76)(0.57)(0.62)(0.52)
Weighted Avg Shares31.89M61.54M61.71M97.92M133.94M
Weighted Avg Shares (Diluted)31.89M61.54M61.71M97.92M133.94M

ProKidney Corp.

NASDAQ:PROK

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.